Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | POLB | P06746 | 3/20 | 0.62 |
| ▸ | DRD2 | P14416 | 1/20 | 0.61 |
| ▸ | HTR2A | P28223 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.57 |
| ▸ | TSHR | P16473 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | NPY2R | P49146 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22422444 | 0.86 | MEN1 (0.79) | MEN1KMT2APOLBDRD2HTR2A | |
| SCHEMBL9653806 | 0.84 | MEN1 (0.85) | MEN1KMT2APOLBDRD2HTR2A | |
| SCHEMBL6977711 | 0.81 | TDP1 (0.67) | MEN1KMT2APOLBDRD2HTR2A | |
| Tert-Butanol SCHEMBL5827581 | 0.81 | ALDH1A1 (0.44) | MEN1KMT2APOLBHTR2AALDH1A1 | |
| SCHEMBL7937794 | 0.80 | ALDH1A1 (0.59) | MEN1KMT2APOLBDRD2HTR2A | |
| SCHEMBL6980847 | 0.79 | TP53 (0.53) | MEN1KMT2AALDH1A1MAPTKDM4E | |
| SCHEMBL1611981 | 0.79 | NR1H2 (0.52) | MEN1KMT2APOLBALDH1A1MAPT | |
| SCHEMBL6981817 | 0.79 | CYP2C9 (0.45) | MEN1KMT2APOLBHTR2AALDH1A1 | |
| SCHEMBL27521377 | 0.78 | ALDH1A1 (0.59) | MEN1KMT2APOLBDRD2HTR2A | |
| SCHEMBL8166343 | 0.77 | MEN1 (1.00) | MEN1KMT2APOLBDRD2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0946539-B1 | SULPHONAMIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS | SMITHKLINE BEECHAM PLC (GB) | 2003-08-13 | — | — | EP | disclosed |
| US-6599904-B2 | 5-HT6 receptor antagonists are believed to be of potential use in the treatment of certain CNS disorders; cognitive memory enhancement | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-07-29 | — | — | US | disclosed |
| US-20030069233-A1 | Sulphonamide derivatives, process for their preparation, and their use as medicaments | SMITHKLINE BEECHAM P.L.C. | 2003-04-10 | — | — | US | disclosed |
| US-6423717-B1 | NERVOUS SYSTEM DISORDERS | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-07-23 | — | — | US | disclosed |
| EP-0946539-A1 | SULPHONAMIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS | SMITHKLINE BEECHAM PLC (GB) | 1999-10-06 | — | — | EP | disclosed |
| WO-1998027081-A1 | SULPHONAMIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS | SMITHKLINE BEECHAM PLC (GB) | 1998-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069233-A1 | Sulphonamide derivatives, process for their preparation, and their use as medicaments | TPMT, MPST, STS | MEN1 1567/4885KMT2A 1602/4885POLB 3308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.